Metabolic Heart Failure: From Mitochondria to Systemic Dysfunction, What Preclinical Models Can and Can’t Tell Us

​Heart failure is increasingly recognized as a systemic metabolic disorder rather than a condition limited to impaired cardiac mechanics. Metabolic heart failure involves disrupted energy utilization, mitochondrial dysfunction, chronic inflammation, insulin resistance, and maladaptive substrate switching. These changes extend beyond the myocardium and affect skeletal muscle, adipose tissue, liver metabolism, and vascular function.

The growing complexity of metabolic heart failure has increased demand for translational preclinical models that capture both cardiac and systemic pathology. However, no single model fully reproduces the human disease state. Each approach offers strengths for studying specific mechanisms while introducing important limitations that influence interpretation and translatability.

Mitochondrial Dysfunction as a Central Driver of Metabolic Heart Failure

The healthy heart requires substantial ATP production to maintain contractile function. Mitochondria generate most of this energy through oxidative phosphorylation, primarily using fatty acids and glucose as substrates. In metabolic heart failure, mitochondrial efficiency declines, reactive oxygen species increase, and ATP production becomes insufficient to meet energetic demands.

These alterations often precede overt structural remodeling. Reduced mitochondrial biogenesis, impaired electron transport chain activity, and altered fatty acid oxidation have all been observed in patients with obesity-associated cardiomyopathy, diabetic cardiomyopathy, and heart failure with preserved ejection fraction (HFpEF).

Preclinical models have helped clarify how mitochondrial stress contributes to disease progression. Common approaches include:

• High-fat diet rodent models to induce obesity and insulin resistance

• Genetic diabetic models such as db/db or ob/ob mice

• Pressure overload models combined with metabolic stressors

• Mitochondrial-targeted transgenic models

These systems allow investigators to evaluate mitochondrial respiration, oxidative stress, substrate utilization, and cardiomyocyte energetics under controlled conditions.

Systemic Metabolic Heart Failure Extends Beyond the Heart

Metabolic heart failure is closely linked to systemic disease. Obesity, type 2 diabetes, chronic kidney disease, and metabolic syndrome contribute to a persistent inflammatory and neurohormonal environment that worsens cardiac remodeling.

Adipose tissue dysfunction plays a major role. Expanded visceral fat depots release inflammatory cytokines and alter adipokine signaling. Skeletal muscle insulin resistance reduces glucose disposal and contributes to impaired exercise tolerance. Hepatic steatosis and altered lipid metabolism further increase circulating metabolic stress.

Many traditional cardiac models isolate the myocardium without capturing these broader interactions. For example, transverse aortic constriction effectively induces pressure overload and hypertrophy but does not fully reproduce the metabolic abnormalities seen in human HFpEF or obesity-related heart failure.

Integrated metabolic models provide greater systemic relevance. Combining dietary induction with hypertension, aging, or renal impairment can better reflect the multifactorial nature of human disease.

Large animal models are mostly impractical at the present time, and are adequately replaced by more efficient small-animal models. In time, as data from large-animal models accumulates, they could improve translational alignment. This is due to closer similarities in cardiac physiology, lipid metabolism, and body composition.

What Translational Endpoints Reveal About Disease Progression

The choice of translational endpoints strongly influences how metabolic heart failure is characterized in preclinical studies. Traditional measures such as ejection fraction alone may fail to detect early metabolic dysfunction.

More informative endpoints often include:

• Myocardial substrate utilization

• Mitochondrial respiratory capacity

• Insulin sensitivity

• Exercise intolerance

• Fibrosis and extracellular matrix remodeling

• Inflammatory biomarker profiling

• Diastolic function measurements

Advanced imaging and telemetry technologies have improved the ability to monitor disease progression longitudinally. Echocardiography, pressure-volume loop analysis, indirect calorimetry, and metabolic phenotyping now allow researchers to connect molecular changes with functional outcomes.

Still, some biomarkers translate inconsistently between species. Rodents exhibit different heart rates, lipid handling, and metabolic flexibility compared with humans. Certain therapeutic responses observed in murine models have not reproduced in clinical trials.

The Limits of Preclinical Modeling in Metabolic Heart Failure

No preclinical model fully captures the heterogeneity of metabolic heart failure. Human patients present with diverse combinations of obesity, hypertension, diabetes, renal dysfunction, frailty, and inflammatory disease. Environmental exposures and genetic variability further complicate disease progression.

Reductionist models remain valuable for mechanistic studies. They help isolate specific signaling pathways and identify potential therapeutic targets. However, relying on a single model can create misleading assumptions about efficacy or safety.

A translational strategy often requires multiple complementary systems. Early mechanistic work may begin in cellular or rodent platforms, followed by validation in larger integrated disease models. Endpoint selection should align with the intended clinical population and therapeutic mechanism.

Importantly, metabolic heart failure continues to evolve as a scientific concept. Emerging evidence suggests that immune signaling, microvascular dysfunction, and altered inter-organ communication may contribute as much as classic energetic impairment. Preclinical systems must continue adapting to reflect these broader disease mechanisms.

Building Better Translational Strategies for Metabolic Heart Failure Research

Developing therapies for metabolic heart failure requires models that balance mechanistic precision with systemic relevance. The most informative programs integrate metabolic, cardiovascular, inflammatory, and functional endpoints across multiple stages of disease progression.

At IPS Theapeutique, translational in vivo studies are designed to evaluate complex cardiometabolic mechanisms using validated disease platforms and clinically relevant endpoints.

Customized study strategies help sponsors assess efficacy, safety, and biomarker responses in models aligned with therapeutic objectives.

As metabolic heart failure research advances, translational rigor will remain critical for reducing late-stage uncertainty and improving decision-making during preclinical development.

Send us a message to learn more and get started.